Main menu
  1. Home
  2.  » 
  3. Events
  4.  » Accelerating Manufacturing for Next Generation hiPSC-Based Clinical Therapies

Accelerating Manufacturing for Next Generation hiPSC-Based Clinical Therapies

Date: Thursday, January 27, 2022
Time: 4 p.m. CET / 10 a.m. EST

Summary: Human induced pluripotent stem cell (hiPSC)-based therapy is currently at the forefront of technology boom and is advancing at a rapid pace. Generating hiPSCs under current Good Manufacturing Practice (cGMP) conditions, tissue sourcing, testing, and scale of production, are now considered as critical components of both clinical and commercial successes. In this webinar, the presenters will share their experiences of the development and manufacturing of hiPSCs. The expert panel will highlight key considerations for driving clinical and commercial success with hiPSCs as starting materials, including aspects such as their derivation, expansion, and differentiation. The experts will also share strategies that can improve the speed, quality, cost of goods, differentiation, and scaling up of hiPSC-based therapies.

Key Learning Objectives:

    • Learn what key criteria a cell therapy developer should use in selecting starting material for hiPSC generation
    • Understand the process development and characterization of hiPSC derived cell therapies and how to address manufacturing challenges
    • Insights into expansion and differentiation of hiPSC in large-scale production.

Co-organized with BioWin



James Crutchley, Ph.D.

Senior Process and Analytical Development Manager,
Catalent Cell & Gene Therapy




Boris Greber, Ph.D.

Head of R&D, iPSC,
Catalent Cell & Gene Therapy




Robert Zweigerdt, Ph
Principal Investigator,
Leibniz Research Laboratories for Biotechnology and Artificial Organs (LEBAO),
Hannover Medical School (MHH), Germany